Trial Profile
Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2021
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors Biscayne Neurotherapeutics; Supernus Pharmaceuticals
- 16 Jan 2018 Status changed from recruiting to completed.
- 19 Oct 2017 Results presented in a Biscayne Neurotherapeutics media release.
- 19 Oct 2017 Results from this trial will be presented at the 8th Annual Sofinnova Japan Biopharma Partnering Conference, according to a Biscayne Neurotherapeutics media release.